Canada Expands Access to Protein-based COVID-19 Booster
Novavax, Inc. recently announced that Health Canada had granted expanded authorization for Nuvaxovid™ for active immunization to prevent COVID-19 as a homologous booster in adults.
"Canadians now have access to our protein-based Nuvaxovid COVID-19 vaccine as an adult booster," said Stanley C. Erck, President and Chief Executive Officer, Novavax, in a press release on November 18, 2022.
"With the winter months upon us, it's important to have options for vaccination to help protect against COVID-19."
Novavax's vaccine (COVID-19 Vaccine (Recombinant protein, Adjuvanted)) (NVX-CoV2373) has been authorized as a heterologous and homologous booster in the U.S., European Union, United Kingdom, Japan, Australia, New Zealand, and Switzerland, as well as several other countries.
Novavax has ongoing trials to explore further the vaccine's immunogenicity and safety as a heterologous booster.
Novavax' patented saponin-based Matrix-M adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.